Targeting Adaptive and Innate Immune Responses with Covalent Aptamers
Open Access
- 10 August 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of the American Chemical Society
Abstract
Covalent aptamers have recently found initial success as tools for fast and selective transfer of labels to target proteins. Here, aptamers targeting protein tyrosine kinase 7 (PTK7) and the mesenchymal-epithelial transition factor (cMet) were functionalized with electrophiles capable of covalently transferring small-molecule immune recruiters. Capitalizing on biotin transfer, aptamers were utilized to trigger activation of universal anti-biotin chimeric antigen receptor (CAR) T cells resulting in selective lysis of PTK7- and cMet-positive cells. Additionally, a cleavable electrophile of 2,4-dinitrophenyl (DNP) hapten transfer was synthesized and utilized for the selective modification of cell surface PTK7 and cMet. The DNP modification elicited the selective activation of complement-dependent cytotoxicity (CDC). These results demonstrate the potential of covalent aptamers as immune-activating and cancer-cell-killing agents.Keywords
Funding Information
- University of Pittsburgh
- National Institute of General Medical Sciences (R01GM142007)
- National Institute of General Medical Sciences (R01GM145086)
This publication has 98 references indexed in Scilit:
- The Evolution of Antibody‐Drug Conjugates: Toward Accurate DAR and Multi‐specificityChemMedChem, 2024
- Clinical Pharmacology Strategies for Bispecific Antibody Development: Learnings from FDA‐Approved Bispecific Antibodies in OncologyClinical Pharmacology & Therapeutics, 2024
- Protein Labeling and Crosslinking by Covalent AptamersAngewandte Chemie International Edition, 2021
- Multivalent Antibody‐Recruiting Macromolecules: Linking Increased Binding Affinity with Enhanced Innate Immune KillingChemBioChem, 2020
- Multifunctional Glycoconjugates for Recruiting Natural Antibodies against Cancer CellsChemistry – A European Journal, 2019
- Development of α‐Gal–Antibody Conjugates to Increase Immune Response by Recruiting Natural AntibodiesAngewandte Chemie International Edition, 2019
- A Nanobody Activation Immunotherapeutic that Selectively Destroys HER2‐Positive Breast Cancer CellsChemBioChem, 2015
- Measured and calculated CD spectra of G‐quartets stacked with the same or opposite polaritiesChirality, 2007
- Cancer immunotherapyBiotechnology Journal, 2006
- Cell‐mediated cytotoxicity to trinitrophenyl‐modified syngeneic lymphocytesEuropean Journal of Immunology, 1974